Phenotypes Associated with This Genotype

Genotype
MGI:3793732

• Allelic Composition: Runx1^tm3Spe/Runx1^tm3Spe; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

decreased thymus weight ( J:131217 )

• after pIpC treatment

increased spleen weight ( J:131217 )

• after pIpC treatment

decreased double-negative T cell number ( J:131217 )

• after pIpC treatment, the number of DN3 and DN4 T cells is decreased 3-fold compared to in wild-type mice

increased double-negative T cell number ( J:131217 )

• after pIpC treatment, the number of DN1 increased 3-fold compared to in wild-type mice

arrested T cell differentiation ( J:131217 )

• after pIpC treatment, T cell maturation is blocked at the DN2 to DN3 stage

abnormal myeloblast morphology/development ( J:151639 )

• following pIpC treatment, myeloid progenitors are increased compared to in untreated mice

thrombocytopenia ( J:131217 )

• two weeks after pIpC treatment

decreased B cell number ( J:151639 )

• following pIpC treatment, bone marrow B cells are lost unlike in untreated controls

decreased hematopoietic stem cell number ( J:151639 )

• following pIpC treatment, the number of long-term repopulating hematopoietic stem cells is decreased compared to in untreated controls

increased hematopoietic stem cell number ( J:151639 )

• following pIpC treatment, the hematopoietic stem cells- enriched LKS+ population is increased unlike in untreated controls

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:267082 )

• all mice die prematurely after receiving ENU, within 15 months after poly (IC) treatment, with myeloid pathology including increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm

immune system

decreased thymus weight ( J:131217 )

• after pIpC treatment

increased spleen weight ( J:131217 )

• after pIpC treatment

decreased double-negative T cell number ( J:131217 )

• after pIpC treatment, the number of DN3 and DN4 T cells is decreased 3-fold compared to in wild-type mice

increased double-negative T cell number ( J:131217 )

• after pIpC treatment, the number of DN1 increased 3-fold compared to in wild-type mice

arrested T cell differentiation ( J:131217 )

• after pIpC treatment, T cell maturation is blocked at the DN2 to DN3 stage

decreased B cell number ( J:151639 )

• following pIpC treatment, bone marrow B cells are lost unlike in untreated controls

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:267082 )

• all mice die prematurely after receiving ENU, within 15 months after poly (IC) treatment

neoplasm

increased incidence of tumors by chemical induction ( J:267082 )

• all mice die prematurely after receiving ENU, within 15 months after poly (IC) treatment, with myeloid pathology including increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm

endocrine/exocrine glands

decreased thymus weight ( J:131217 )

• after pIpC treatment

growth/size/body

increased spleen weight ( J:131217 )

• after pIpC treatment